While the sensitivity of IDH-mutant cells to BCL2 inhibition in vitro is dependent on 2-HG [110], the situation appears to be more complex in vivo with the combination of IDH inhibitors and Venetoclax (administered concurrently) demonstrating superior anti-leukaemia efficacy in mouse models and early clinical trials [112,113]. This evidence concerns the gene IDH2 and leukemia.